Inclusion Criteria

DISEASE CHARACTERISTICS:

- Biopsy-proven carcinoma of the prostate

- Has chosen to undergo a radical prostatectomy (or cystoprostatectomy) for treatment
of disease after the medical team has presented all possible treatment options

PATIENT CHARACTERISTICS:

- ECOG performance status 0-1

- BUN/creatinine, liver enzymes, complete blood count, and PT/PTT/INR normal

- Agrees to have prostate biopsy blocks provided to the study for evaluation

- Agrees to consume a standardized vitamin and mineral supplement and avoid other
nutritional, dietary, or alternative medications/supplements for the duration of the
study

- No other active malignancy that requires therapy

- No history of pituitary hormone diseases that currently require supplemental hormonal
administration (thyroid hormones, ACTH, growth hormone) or other endocrine disorders
requiring hormone administration (except for diabetes or osteoporosis)

- No medical conditions, including malabsorptive disorders or other metabolic disorders
requiring special dietary recommendations, severe constipation, recent history of
anemia or iron deficiency, or hypertension that requires a strict low-sodium diet

- No known allergy to soy or tomato components

PRIOR CONCURRENT THERAPY:

- No prior traumatic or surgical castration

- No concurrent neoadjuvant hormonal therapy or chemotherapy (other clinical trials)

- No other concurrent lycopene, soy dietary supplements, or "alternative" products
(i.e., PC-SPES, or Saw Palmetto)

- No concurrent finasteride (Proscar) or other hormonal agents for
chemoprevention/treatment of benign prostate hyperplasia

- No concurrent prescription medications for urinary outlet obstructive symptoms

- No concurrent non-prescription substances to improve urinary tract symptoms (i.e.,
Saw Palmetto or other herbal or alternative products)